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Abstract 
Though hepatitis C virus (HCV) is the most common blood-borne infection in the United States, 
the epidemic has gone largely unnoticed, such that an estimated 75% of people living with HCV 
are undiagnosed. As a result, the Department of Health and Human Services (DHHS) has 
released a new Hepatitis Action Plan.  This plan calls for a national commitment to educating 
high-risk communities about HCV and to testing, care and treatment within these communities to 
prevent HCV transmission and liver disease. The appropriate model for achieving these goals is 
unknown as is the acceptance of such interventions, particularly when many high-risk 
individuals may not have access to HCV specific medical treatment. We set out to assess 
attitudes about HCV screening and knowledge about HCV disease and treatment at several 
community-based testing sites that serve high-risk populations.  This assessment was paired with 
a brief HCV educational intervention. Participants (N=140) were surveyed at five sites, including 
two homeless shelters, two drug rehabilitation centers, and a women’s “drop-in” center.  
Personal acceptance of HCV testing was almost unanimous, and 90% of participants reported 
that they would still want to be tested even if they were unable to receive HCV treatment.  
Baseline hepatitis C knowledge was poor; however, the brief educational intervention 
significantly improved knowledge and increased acceptability of testing when medical access 
issues were explicitly stated.  Conclusion:   Despite poor HCV knowledge and limited access to 
health care, hepatitis C screening was highly acceptable in this study population. As underscored 
by the DHHS action plan, this assessment supports HCV screening, education, and linkage to 
care in high-risk communities, even when access to HCV medical care may be difficult.  
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Introduction 
Hepatitis C virus (HCV) is the most common blood-borne infection in the United States (US), 
with an estimated 4 million persons chronically infected 
1
. It is the leading cause of end-stage 
liver disease and hepatocellular carcinoma, as well as the most common indication for liver 
transplantation 
2,3
.  Until recently, this epidemic has gone largely unnoticed.  Consequently, 75% 
of persons living with HCV are unaware of their infection 
4,5
 and thus are at risk of developing 
sequelae such as cirrhosis and hepatocellular carcinoma, without an opportunity for treatment 
and appropriate disease management. 
 
The burden of the HCV epidemic disproportionately affects certain US populations, resulting in 
significant healthcare disparities. Specifically, the prevalence of HCV is highest among persons 
with a history of intravenous drug use, incarcerated populations, homeless adults, and baby 
boomers (persons born between 1945-1965)
2,6-8
.  African Americans are twice as likely to be 
infected when compared to the general US population 
9
.  Furthermore, approximately one third 
of human immunodeficiency virus (HIV)-infected patients are co-infected with HCV, with HIV 
positive men who have sex with men becoming an increasingly recognized risk group 
10
. Many 
of these high-risk populations are hard-to-reach, and many do not have regular access to 
healthcare 
11
.   
 
The magnitude of infection within the US population, and the extent to which HCV has been 
largely undiagnosed, has invigorated a national commitment to improve awareness, screening, 
and linkage to care for this disease.  On May 12, 2011, the Department of Health and Human 
Services (DHHS) issued “Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the 
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Prevention, Care and Treatment of Viral Hepatitis.”  This action plan calls for a targeted HCV 
education strategy for high-risk communities, and also emphasizes outreach to priority 
populations to provide opportunities to get tested and seek care.  The appropriate model for 
achieving these goals is unknown as is the acceptance of such interventions, particularly when 
many high-risk individuals may not have access to HCV specific medical treatment.  We set out 
to assess attitudes surrounding HCV screening, as well as knowledge regarding HCV disease and 
treatment at several community-based testing sites that serve high-risk populations. This 
assessment was paired with a brief HCV educational intervention, followed by post-intervention 
assessment of changes in knowledge and attitudes.  
 
Methods 
Setting and Participants 
Sites were chosen from a list of community based HIV/sexually transmitted diseases testing sites 
utilized by the local public health department (Wake County Human Services). A convenience 
sample of persons attending each of these settings was surveyed.  The inclusion criteria were: 1) 
speak/understand English; 2) age 18 or older; (3) willingness to complete a pre and post-test 
survey instrument and participate in a short educational intervention.  The survey was 
anonymous and clearly labeled as to its purpose (research study), and verbal consent was 
performed.  No identifying information was obtained from subjects, and they were compensated 
for participation with a five dollar grocery store gift card.  The study was exempted from 
institutional review board review by the Duke University Medical Center Institutional Review 
Board. 
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Study Intervention 
An educational intervention was given as well as pre- and post-intervention surveys.  Pre- and 
post-intervention survey instruments were administered verbally to participants to assess 
knowledge and attitudes surrounding hepatitis C disease, testing, and treatment.   
 
The survey instrument assessed socio-demographic information, access to healthcare, knowledge 
of HCV, and attitudes toward community HCV screening. The survey was first piloted among 
patients in the Duke Infectious Diseases clinic to assess question comprehension, and revisions 
were made accordingly. To ensure full comprehension, study investigators verbally administered 
the survey instruments to all participants. The post-intervention survey consisted of a subset of 
the pre-intervention questions.      
 
The educational intervention consisted of a brief (approximately 15 minute) standardized 
discussion of the epidemiology of HCV, clinical significance, care and treatment options, and 
preventative strategies, followed by a question/answer session. A spiral-bound flip-book with 
diagrams was used with the discussion.  The intervention was designed with the assistance of 
professional health educators and was directed toward a fifth grade education level.  The same 
investigator (B.N.) delivered the educational program at each site in order to maximize the 
consistency of the educational intervention across sites.  
 
Statistical Analysis 
The studied was powered on the primary objective: assessment of screening acceptability. We 
chose a sample size that would permit adequate assessment of whether a majority (i.e., >50%) of 
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participants felt that HCV screening would be acceptable in their community. Assuming that the 
true rate of HCV testing acceptance in the community was 60% in the underlying population, we 
needed 153 participants to exclude an acceptability rate of <50% with 80% power at a 5% type 1 
error rate, using a one-sided significance test.  The study was stopped early due to overwhelming 
acceptance of screening.    
 
Continuous variables were summarized using medians/quartiles or means/standard deviations, as 
appropriate to the distribution.  Categorical variables were summarized with frequency 
counts/proportions.  Changes in knowledge and acceptance of HCV testing were assessed using 
the McNemar test to compare baseline and post-education responses.  Answers of “not sure” 
were considered not correct (knowledge) or negative for acceptance. We created a composite 
knowledge score from 18 knowledge-related questions, assigning each correct answer one point.  
Bivariate associations between knowledge and pre-selected predictor variables were assessed 
using t-tests with categorical variables or Pearson correlations with continuous variables. All 
variables significantly associated with knowledge at an alpha of <0.05 were then entered into a 
multivariable linear regression model, centering the age variable in the model.  
 
Results 
Demographics 
One hundred forty participants were surveyed at 5 sites, including 2 homeless shelters, 2 drug 
rehabilitation centers, and a women’s “drop-in” center.  The majority of participants were male 
(66%) and African American (57%)  (Table 1).  The median age was 43 years old, with a range 
of 18 to 62 years.  Participants varied in education levels, with 16% having stopped education 
9 
 
after elementary school. Most people had no health insurance (73%), and less than half stated 
they had a regular doctor (49%). Ninety-five percent of participants had heard of HCV, 56% said 
they knew someone with the disease, and 18% of participants stated that they had been 
diagnosed with HCV.   Though all of these participants were surveyed at community centers 
serving high-risk individuals, 32% of participants still believed they were “not at all” likely to 
get HCV. 
 
Baseline Knowledge 
Baseline knowledge and attitudes regarding HCV and HCV screening are presented in Table 2. 
Baseline knowledge about HCV acquisition was variable.  Although 90% of people knew that 
injecting drugs and getting a homemade tattoo are risk factors for HCV, 22% of people did not 
think sexual acquisition was possible, 17% thought HCV was transmitted from public toilets, and 
28% thought HCV was transmitted from coughing or sneezing. Many people did not know what 
risk factors were associated with disease progression. Participants’ baseline knowledge 
concerning HCV treatment was also low.  Seventy-six percent of participants believed that 
everyone diagnosed with HCV needed treatment, yet 65% either did not think HCV could be 
cured or did not know if it could be cured.  Ninety-eight percent of participants said they would 
want treatment if they tested positive for HCV; however, 63% did not know about treatment side 
effects or thought that side effects of therapy were minimal.   
 
Baseline Attitudes 
Ninety-seven percent of participants stated they would get a free HCV test if it were offered, 
with 90% reporting that they would still want to be tested even if they were not able to receive 
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treatment. When told that, if positive, they would be offered free vaccines against hepatitis A and 
B, or lifestyle advice on how to stay healthy with HCV, more people wanted to be tested even if 
treatment was not accessible to them (95% and 96% respectively).  
 
Almost all participants (99%) said that they wanted free HCV testing in their community, but 
participants were less positive when asked if other people in their community would want free 
HCV testing in the community (86%). Almost half (49%) thought that offering community-
based screening without the availability of universal treatment would be problematic.  Also, only 
39% of participants believed that others in their community who tested positive for HCV would 
drink less alcohol.  But most believed that HCV positive persons would get vaccinated against 
hepatitis A and hepatitis B (83%) or go to the doctor for treatment (76%).  
 
Changes in Knowledge and Attitudes Post-Intervention  
The brief educational intervention significantly improved knowledge about HCV (Table 3).  
Eighty-one (81%) percent of participants understood that treatment was not necessary for 
everyone with HCV, as compared to 10% pre-education (p<0.0001).  Ninety percent (90%)of 
participants gave correct responses regarding HCV cure rates after the educational intervention, 
as opposed to 33% pre-education (p<0.0001).  After learning about the deleterious effects of 
alcohol in patients with HCV, significantly more participants believed that people in the 
community who tested positive for HCV would drink less alcohol (p=0.003).  Attitudes toward 
personal acceptance of HCV testing did not change after education since almost all participants 
wanted to be tested on the pre-intervention survey. However, the participants’ perceived 
acceptability of HCV screening among other members of the community did increase after 
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education. Importantly, participants were significantly less likely after education to believe that 
offering community-based HCV screening without guarantee of universal treatment would be 
problematic  (49% pre-intervention believed this would be problematic vs. 35% post-education, 
p=0.02). 
 
Knowledge Score and Associations 
The mean baseline knowledge score was 9.9 (SD 3.3), ranging from 0-18. Characteristics 
associated with greater knowledge were male gender, white race, younger age, and knowing 
someone with HCV (Table 4). Interestingly, participants who did not want to be tested for HCV 
if they were not guaranteed treatment had significantly lower knowledge scores than people who 
wanted to know their HCV status despite availability of treatment (p=0.003).  When 
dichotomizing age based on the CDC screening recommendations, participants greater than 45 
years old (baby boomer generation) had mean knowledge scores that were lower than younger 
participants (9.5 vs. 10.4, p=0.08).  In multivariable analysis, white race, male gender, knowing a 
person with HCV, and wanting HCV testing even if treatment could not be offered remained 
associated with higher knowledge scores (Table 5).   
 
 
Discussion 
Community-based screening programs have the potential to reach persons at significant risk for 
HCV who do not normally access healthcare 
12,13
; however, it is important to understand the 
acceptability of HCV testing in a group that may have limited access to treatment.  This issue is 
particularly important when the agency providing screening (the public health department) has 
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no resources to provide treatment, and therefore limited control over whether persons who test 
positive are engaged in treatment.  In this study, we found that people who access community 
based, non-traditional testing sites were highly accepting of integrating HCV-testing into 
community-wide screening programs. On the other hand, high-risk individuals had relatively 
rather poor knowledge about HCV.  Nonetheless, a relatively easy on-site educational 
intervention significantly improved HCV knowledge and also increased acceptability of testing.  
 
HCV testing of high-risk groups is cost-effective 
14-16
, yet early diagnosis continues to be 
inadequate 
17,18
.  Community-based testing may be able to identify persons living with HCV who 
do not regularly access healthcare but who are along some of the highest-risk populations. 
4,19,20
. 
Early HCV detection provides an opportunity for low-cost interventions that can decrease the 
risk of liver disease including alcohol reduction counseling, HIV testing, and immunization 
against hepatitis A and B. Furthermore, earlier identification can result in access to therapies at 
an earlier stage of liver disease which is associated with an improved treatment response rate 
(19) and less risk of long term complications including cirrhosis, end-stage liver disease, 
hepatocellular carcinoma and need for transplant. As newer medical therapies with improved 
efficacy and side effect profiles become increasingly available, early identification of disease by 
HCV screening will have greater potential to reduce poor outcomes.   
 
Although community-based screening offers a number of opportunities for improved 
intervention, testing vulnerable populations who may not have full access to treatment raises the 
potential for misunderstanding and mistrust in these communities. To our knowledge, this is the 
first study to directly assess acceptability rates of community based HCV screening when access 
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issues were explicitly stated.   We found that acceptability of screening was almost universal in 
this population, and remained high even when participants were told that they would not be able 
to receive treatment. Ninety seven percent of participants said that they would personally obtain 
a free HCV test, and 99% stated they would want free HCV testing in their community.  Even 
when told they would not be able to receive treatment, 90% of participants said they would still 
want to know their HCV status.  When told that free hepatitis A/B vaccination or advice on harm 
reduction (e.g. abstinence from alcohol), but no antiviral treatment, could be offered, almost all 
participants again wanted to be tested regardless of availability of medical therapy.  This is 
important because the public health department often can provide free vaccinations and 
counseling as part of a community-based screening program.         
 
In contrast to the high rates of acceptance of HCV screening, knowledge regarding HCV was 
relatively poor. This lack of knowledge was surprising given over half of participants reported 
knowing someone with HCV and 18% of participants endorsed personal infection with HCV. 
Our work supports prior investigations that have shown significant gaps in HCV knowledge in 
high-risk groups, such as persons living with HIV and intravenous drug users 
21-23
. Similar to 
these studies, we found that lack of knowledge was associated with African American race and 
older age, two groups that are disproportionately afflicted by this disease.  Participants 
demonstrated poor knowledge about HCV acquisition, which may impact a person’s ability to 
make choices that protect themselves and prevent transmission to others in their community.   
We also found a large percentage of people who did not know that alcohol or HIV could worsen 
HCV disease progression, and even fewer knew that obesity has a negative effect on liver health. 
This dearth of information makes it difficult for HCV positive people to make healthy lifestyle 
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choices when living with HCV.  There were also significant misconceptions in understanding 
HCV therapy, as most people believed all HCV positive persons needed to be treated.  Finally, a 
majority of participants were unsure or did not think that HCV could be cured, and over half 
carried erroneous beliefs regarding HCV treatment side effects. This hinders the ability of HCV 
positive persons to appropriately interpret their disease and lessens their ability to access care 
and treatment
24
. 
Fortunately, a brief educational intervention significantly improved HCV knowledge among the 
participants. Almost all areas of HCV knowledge improved post-intervention, with the greatest 
changes occurring in understanding of treatment.  Notably, improvement in HCV knowledge has 
been shown to improve compliance with linkage to HCV care
25
.  
 
By increasing knowledge, our educational tool also increased acceptance rates for HCV testing.  
Although personal screening was highly accepted, some participants expressed concern 
regarding the community’s desire for screening if access to treatment was not universal. That 
said, those who were concerned about community acceptance demonstrated significantly more 
positive attitudes toward of HCV screening after education was provided. Furthermore, the small 
minority of individuals hesitant to be personally tested without a guarantee of treatment 
demonstrated lower HCV knowledge scores, even when adjusted for other variables. These 
findings underscore the importance of continued community education to enhance both 
knowledge of HCV and acceptance of community-based HCV screening. 
 
This study has several limitations.  Our population consisted of a convenience sample of high-
risk individuals that access non-traditional testing sites of an urban health department in the 
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southern United States.  Many of the participants were in drug/alcohol rehabilitation programs, 
and may have been more motivated to provide positive responses to survey questions than others 
in their communities.  Our results therefore may not be generalizable to the entire at-risk 
population.  Second, we assessed the impact of the educational intervention immediately 
following the discussion, so we cannot comment as to whether the improvement in knowledge 
was durable.  Verbal administration of the surveys may have also biased the participants to 
provide more positive responses than a written instrument.  Finally, since a member of the study 
team verbally administered the education intervention, its reproducibility cannot be guaranteed.  
 
Conclusion 
In this population of individuals at high risk for HCV acceptance of community-based HCV 
screening, even without guarantees of access to treatment, were very high.  Despite 
inconsistencies in availability of HCV treatment and poor knowledge regarding HCV, high-risk 
patients are ready to know their HCV status.  A comprehensive screening strategy that 
implements brief on-site education can aid in improving HCV knowledge, and encourage testing.  
The impact of such a program on change in behavior and engagement in care is yet to be 
determined, but community based screening programs in high-risk populations are the right place 
to start.   
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Table 1: Patient Demographics 
 
Patient Characteristics % (n=140) 
Male 66% (92) 
Age (median, IQR) 46 (33,54) 
Race 
  White 
  Black 
  Other 
 
37% (52) 
57% (80) 
6% (8) 
Education 
  Elementary 
  High School 
  Some College 
  Finished College 
 
16% (22) 
39% (55) 
31% (43) 
14% (20) 
Insurance 
  None 
  Medicaid/Medicare 
  Private 
  VA/Other 
 
73% (102) 
12% (17) 
6% (9) 
9% (12) 
Has Regular Doctor 49% (68) 
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Table 2: Proportions and Frequencies of Pre-test Survey Answers 
Questions  Yes No Unsure 
Have you heard of HCV? 95% (133) 4% (6) 0.7% (1) 
Do you know anyone who has HCV? 56% (79) 39% (55) 4% (6) 
Have you been told you have HCV? 18% (25) 80% (112) 2% (3) 
How likely do you think you are to get HCV? 
  Not at all 
  Somewhat 
  Very 
  Not sure 
 
32% (42) 
28% (36) 
16% (21) 
24% (31) 
  
How do you think people get HCV infection?*    
  Having Sex? 56% (78) 22% (31) 22% (31) 
  Shooting up (injecting) drugs? 90% (126) 1% (2) 9% (12) 
  Using public toilets? 17%1 (24) 60% (84) 23% (32) 
  Sharing supplies for snorting drugs?             54% (75) 26% (37) 20% (28) 
  Coughing/sneezing on someone? 28% (39) 51% (72) 21% (29) 
  Getting a homemade tattoo? 90% (125) 2% (3) 9% (12) 
Which of the following problems can HCV cause 
to your body?* 
   
  Stroke? 11% (16) 31% (44) 57% (80) 
  Cirrhosis/Liver Failure? 81% (114) 3% (4) 16% (22) 
  Blindness? 38% (53) 15% (21) 47% (66) 
  Liver Cancer? 62% (87) 9% (13) 27% (40) 
22 
 
  Heart Attack? 18% (25) 33% (47) 49% (68) 
  Death? 79% (111) 3% (4) 18% (25) 
What makes HCV worse for the people that have 
it?* 
   
  Drinking coffee? 4% (5) 56% (78) 41% (57) 
  Drinking Alcohol? 82% (115) 6% (9) 11% (16) 
  HIV infection? 82% (115) 3% (4) 15% (21) 
  Being obese? 34% (47) 26% (36) 41% (57) 
Does everyone who has HCV need treatment?* 76% (107) 10% (14) 14% (19) 
How many people who get treated for HCV, get 
cured?* 
   All 
   Some 
   None 
   Not sure 
 
 
3% (4) 
33% (46) 
29% (40) 
36% (50) 
  
Do you think that the side effects of HCV 
treatment are very bad? 
   Yes 
   Somewhat 
   No 
   Not Sure 
 
 
21% (29) 
17% (24) 
14% (19) 
49% (68) 
  
Would you get a free blood test for HCV? 97% (136) 2% (3) 1% (1) 
Would you want to get treated for HCV if you 98% (137) 1% (1) 1% (2) 
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tested positive? 
Would you want to be tested for HCV, if when 
you tested positive you could get free treatment? 
99% (139) 
 
0 (0) 
 
1% (1) 
Would you still want to be tested, if you were told 
you could not be offered treatment? 
90% (126) 
 
10% (14) 
 
0% (0) 
Would you still want to be tested if you were told 
you could not be offered treatment, but you could 
get free vaccines against HAV/HBV?   
95% (133) 
 
5% (7) 
 
0% (0) 
Would you still want to be tested if you were told 
you could not be offered treatment, but you could 
get lifestyle advice on how to stay healthy with 
HCV? 
96% (134) 
 
4% (5) 
 
1% (1) 
Do you want free HCV testing in your 
community? 
99% (139) 0% (0) 1% (1) 
Do you think other people would want free HCV 
testing? 
86% (121) 
 
1% (1) 
 
13% (18) 
If people in the community tested positive for 
HCV, do you think they would do the following 
things if they were told it would help them? 
   
  Drink less alcohol? 39% (55) 24% (33) 37% (52) 
  Get a shot against HAV/HBV? 83% (116) 2% (3) 15% (21) 
  Go to the doctor for treatment? 76% (107) 1% (92) 22% (31) 
Do you think it will be a problem if we tested for 49% (69) 39%(54) 12% (17) 
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HCV in your community but might not be able to 
offer treatment to everyone who’s positive? 
  
*Questions that were used in composite knowledge score 
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Table 3: Analysis of Pre and Posttest Changes of Answers 
 
Knowledge Related Questions Pre-Test  
% Correct 
Post-Test  
% Correct  
p-value 
(McNemar) 
How do you think people get HCV?    
  Having Sex? 56% 84% <0.0001 
  Shooting up (injecting) drugs? 90% 98% 0.001 
  Using public toilets? 60% 95% <0.0001 
  Sharing supplies for snorting drugs?             54% 85% <0.0001 
  Coughing/sneezing on someone? 52% 94% <0.0001 
  Getting a homemade tattoo? 89% 97% 0.0074 
    
What makes HCV worse for the people who 
have it? 
   
  Drinking coffee? 45% 86% <0.0001 
  Drinking Alcohol? 82% 96% <0.0001 
  HIV infection? 82% 89% 0.121 
  Being obese? 33% 80% <0.0001 
    
Does everyone who has HCV need treatment? 10% 81% <0.0001 
How many people who get treated for HCV get 
cured? 
33% 
 
90% <0.0001 
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Attitude Related Questions Pre-Test % 
Answered 
Yes 
Post-test % 
Answered 
Yes 
p-value 
(McNemar) 
Would you want to be tested for HCV, if when 
you tested positive you could get free treatment? 
99% 100% 1.0 
Would you still want to be tested, if you were 
told you could not be offered treatment? 
90% 
 
90% 
 
1.0 
Would you still want to be tested if you were 
told you could not be offered treatment, but you 
could get free vaccines against HAV/HBV?  
95% 96% 
 
.727 
Would you still want to be tested if you were 
told you could not be offered treatment, but you 
could get lifestyle advice on how to stay healthy 
with HCV?  
96% 95% 1.0 
Do you want free HCV testing in your 
community? 
99% 97% 0.25 
Do you think other people would want free HCV 
testing? 
86% 92% 0.077 
Do you think it will be a problem if we tested for 
HCV in your community but might not be able 
to offer treatment to everyone who’s positive? 
49% 35% 0.019 
If people tested positive for HCV, do you think 
people would do the following if they were told 
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it would help them?  
  Drink less alcohol? 39% 54% 0.003 
  Get a shot against HAV/HBV? 83% 86% .383 
  Go to the doctor for treatment? 76% 79% .524 
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Table 4: Bivariate Analysis of Knowledge Score  
Variable (n) Mean (SD) Knowledge Score 
or correlation coefficient 
p-value 
Total  9.9 (3.3)  
Age (140) r= -0.17 0.04 
Gender 
  Male (92) 
  Female (48)   
 
10.4 (.35) 
9.1 (.44) 
 
0.02 
Race 
   White (52) 
   Non-White (88) 
 
10.8 (2.8) 
9.4 (3.5) 
 
 
0.02 
Regular Doctor 
   Yes (68) 
   No (72) 
 
9.8 (3.0) 
10.1 (3.6) 
 
0.64 
Education 
   Elementary (22) 
   High School (55) 
   Some College 
   Finished College 
 
9.4 (3.6) 
9.5 (3.4) 
10.1 (3.0) 
11.5 (2.9) 
 
 
0.11 
Insurance 
   Yes (102) 
   No (38) 
 
10.0 (3.5) 
9.8 (2.7) 
 
0.83 
Do you know anyone with   
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HCV? 
   Yes (79) 
   No (55) 
10.5 (3.1) 
9.3 (3.5) 
0.03 
Do you have HCV? 
   Yes (25) 
   No (112) 
 
10.6 (3.8) 
9.8 (3.2) 
 
0.24 
Would you still want to be 
tested if you could not get 
treatment? 
   Yes (126) 
   No (14) 
 
 
10.2 (3.1) 
7.5 (3.7) 
 
 
0.003 
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Table 5: Multivariable Analysis of Characteristics Associated with Knowledge Score 
Characteristics* Adjusted Mean p-value Beta coefficient (s.e.) 
Age 
   31 years (-1SD below mean) 
   56 years (+1SD above mean) 
 
10.37 
9.72 
0.271 -.026 (.024) 
Gender 
   Male 
   Female 
 
10.60 
8.84 
 
0.002 
 
-1.76 (.566) 
Race    
   White 
   Non-White 
 
10.70 
9.57 
 
0.065 
 
-1.13 (.605) 
Do you know someone with 
HCV? 
   No 
   Yes 
 
9.28 
10.50 
 
0.025 
 
1.22 (.540) 
Would want to be tested even if 
can’t be offered treatment? 
   No 
   Yes 
 
 
7.71 
10.25 
 
0.005 
 
2.53 (.890) 
*Referent group placed first under each categor 
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HCV and HIV Coinfection: A Review of the literature 
Introduction 
Chronic hepatitis C is a global health problem, with an estimated 170 million persons infected 
worldwide
26
.  In industrialized countries, HCV is the leading cause of end-stage liver disease and 
hepatocellular carcinoma, as well as the most common indication for liver transplantation 
2,3
.  
Due to shared routes of acquisition, many persons with HIV are also chronically infected with 
Hepatitis C.  Of the 33 million persons living with HIV globally, it is estimated that 30% are 
dually infected with HCV
27
.    Liver-related mortality, associated with HCV, has been found to 
be a leading cause of death for HIV patients in the era of highly active antiretroviral treatment.  
The burden of HCV in the US is predicted to peak in 2030, resulting in significant increases in 
rates of cirrhosis, end-stage-liver disease, and hepatocellular carcinoma
28
. This clinical and 
financial burden will be greatest among HIV-infected individuals given the more rapid disease 
progression and thus requires immediate attention. HIV/HCV co-infected patients use more 
health care than either their HCV or HIV mono-infected counterparts, and this is reflected in the 
increased outpatient visits, emergency department visits, and hospital admissions
29
.  Although 
historically HIV-infection was a baseline risk factor for poorer response to therapy, this no 
longer appears to be true with newer HCV medications. Thus, consideration of HCV treatment is 
recommended in all HIV/HCV co-infected patients. Here I will review the latest developments in 
epidemiology, transmission, and therapeutics and will provide a roadmap for the management of 
the co-infected patient. 
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Transmission 
The transmission of HCV is most efficient through blood-to-blood contact, thus risk factors 
associated with parenteral exposure to both HIV and HCV viruses influence the risk of co-
infection.  Prior to 1992, exposure to HCV through contaminated blood products was common, 
and many hemophiliacs were infected with both HIV and HCV via blood transfusions.  Since the 
availability of routine screening of blood products, this mode of transmission has significantly 
reduced. Currently, IVDU remains the primary mode of transmission in industrialized countries, 
such that the prevalence of HIV/HCV co-infection is as high as 77% in this population
30
.    
Sexual Transmission of HCV 
Sexual transmission of HCV is believed to be inefficient, although there may be host factors that 
can influence the risk. Biological plausibility for sexual transmission is supported by the 
isolation of HCV in both semen and vaginal secretions
31-33
.  However, early cross sectional 
studies of partners of HCV mono-infected heterosexual hemophiliac men showed almost 
negligible risk of sexual transmission, and partners that were HCV positive all had other risk 
factors for HCV 
34-36
.   A prospective study of heterosexual serodiscordant partners consisted of 
529 person-years of follow up with more than 40,000 vaginal or anal penetrations, with no 
transmission of HCV between partners
37
. This was further supported by a prospective study of 
895 heterosexual monogamous couples who were HCV serodiscordant and did not use condoms. 
After 10 years of follow-up there was no evidence of sexual transmission of HCV between 
partners
38
.   Studies involving HCV mono-infected MSM also showed very low risk of sexual 
transmission, even when participants engaged in unprotected anal sex
39,40
.    
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Although sexual transmission in the setting of HCV mono-infection is rare, there is good 
argument that active HIV-infection may increase host susceptibility to HCV sexual transmission. 
The presence of active HIV infection has been associated with an increased risk of sexual 
acquisition of HCV even in early studies of heterosexual partners.  An early cross sectional study 
of 231 heterosexual hemophiliacs found that HIV was almost four times more likely to be 
transmitted than HCV to a female partner, and that in all cases of HCV transmission the partner 
was also infected with HIV
34
. Three percent of female sexual partners of HIV/HCV co-infected 
hemophiliacs became infected with HCV, compared to zero of the female partners of HIV-
negative/HCV positive hemophiliacs.  Furthermore, the large Women’s Interagency HIV Study 
found that, even after controlling for IVDU, HIV infected women were almost two times as 
likely to have HCV as HIV-negative women
41
.  Many studies report increased sexual risk 
behaviors and the presence of pre-existing STDs, as well as HIV positivity, to account for the 
increase risk of HCV heterosexual transmission
42-46
.  
HIV positive MSM may have the greatest risk of sexual transmission of HCV. Over the last 
decade there have been increasing reports of acute HCV outbreaks among HIV-positive MSM in 
Europe
47-49
, Australia
50
, and the United States
51-53
.  Phylogenetic analysis has revealed an MSM-
specific strain of HCV in HIV positive cohorts in the Netherlands, France, and the UK.  In 
Amsterdam a large prospective study of 1836 MSM were studied over the course of almost 2 
decades, 1984-2003. Pylogenetic analysis found that 83% of the MSM infected after 2000 had a 
strain similar to another participant, typical of a common source of infection. These strains 
differed significantly from the strains found in IVDUs, suggesting needle sharing was an 
unlikely source of infection.  The lack of clustering prior to 2000 supports recent transmission 
and a growing epidemic among HIV positive MSM.  An international phylogenetic study then 
34 
 
attempted to associate these distinct outbreaks throughout Europe.  A large study conducted in 
England, The Netherlands, France, Germany, and Australia found 11 strongly supported 
monophyletic transmission clusters of MSM specific strains of HCV. Overall, 84% of 
participants were infected with an HCV strain that was most similar to a strain in another study 
participant. The participants from Australia, of which half were IDU rather than MSM, also 
clustered together but did not overlap with the individuals from Europe. Molecular clock analysis 
suggested that the majority of these transmissions occurred after 1996. This study is evidence of 
an emerging international network of HCV transmission among the HIV positive MSM 
community, and similar sexual networks of transmission have been identified in NYC. 
54
.  
The fact that phylogenetic has identified numerous strains of HCV that are representative of 
HCV transmission clusters refutes the notion that this epidemic is related to the virus, and instead 
supports host related factors. Co-infections are recognized risk factors for viral transmission, 
HSV and HIV being excellent examples, yet how HIV might increase HCV sexual transmission 
is not fully understood. There is evidence that specific behaviors can increase risk of HCV 
infection.  Several well designed cohort studies support a relationship between high-risk sexual 
practices such as unprotected anal sex, group sex, use of sex toys, and fisting and acquisition of 
HCV. With increasing reports of acute HCV infection among the HIV-infected MSM, the overall 
prevalence of HCV among HIV-infected MSM is increasing.  In one study in Amsterdam the 
prevalence of HCV among HIV positive MSM increased from 1-4% before 2000, to 21% in 
2008. This is compared with an estimated prevalence of 0.4% among HIV negative MSM
55
. 
 
35 
 
Natural History and Progression of Disease 
HIV on HCV 
With the advent of highly active antiretroviral therapy, patients with HIV are living longer and 
are less frequently dying from AIDS related complications. As a result, there is growing 
emergence of morbidity and mortality from HCV among HIV positive persons. In fact, liver-
related deaths were noted to be the primary cause of non-AIDS related mortality among one 
large cohort of HIV-infected individuals
56
, and HCV related mortality is responsible for up to 
11.5% of overall mortality in cohorts of HIV positive individuals
57
.  In general, HIV/HCV co-
infected individuals have higher mortality than HIV monoinfected individuals, and almost half of 
all deaths among the co-infected are found to be due to liver-related causes
58
.  
HIV infection can increase HCV viremia by 2-to-8 fold, resulting in significant decrease in 
spontaneous clearance of acute HCV as compared to mono-infected individuals
59
, resulting in 
most HIV positive individuals going on to develop chronic infection. Individuals with chronic 
Hepatitis C develop varying degrees of fibrosis of the liver, over varying degrees of time. This 
fibrosis can ultimately lead to cirrhosis, producing liver failure, hepatocellular carcinoma, or 
death.  Progression to cirrhosis is more common among HIV/HCV co-infected individuals.  In 
one meta-analysis, HIV/HCV co-infected individuals were found to be twice as likely to develop 
cirrhosis, and 6 times as likely to develop decompensated liver disease as compared to their HCV 
mono-infected counterparts
60
.   
Risk factors for progression to liver fibrosis are similar to HCV mono-infected and include 
fibrosis stage, older age, duration of infection, alcohol consumption, male sex, high BMI, 
diabetes, and steatosis
61
.  HIV co-infection has also been shown to be an independent predictor 
of liver progression, with various factors believed to be the cause. The rate of cirrhosis is 2 to 5 
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fold higher among HIV/HCV.  Certainly weaker immune status has been proposed, and many 
studies have shown that lower CD4 counts, both current and nadir, do lead HCV persistence, 
more rapid liver fibrosis, and poor interferon treatment response. In HIV-infected patients with 
compensated liver cirrhosis, mortality was high and associated with older age, CD4 counts <200, 
and detectable HIV viral loads
62
.  
As HAART has become more widely available, there have been mixed reports as to whether co-
infection is indeed still a risk for worsened HCV liver disease among patients on effective 
HAART therapy. In general, studies have overwhelmingly shown that HAART and HIV viral 
suppression independently reduce liver fibrosis among HIV/HCV co-infected individuals
62-64
. It 
is plausible that suppressed viral load itself can reduce liver damage through reduced HIV 
replication in fibrosis promoting stellate cells
65
, and reduce proinflammatory cytokines
66
.  
Reduced HCV exposure to the HIV gp120 protein has been shown to decrease HCV viral 
replication, and thus may be another mechanism of slower fibrosis among patients with HIV 
viral suppression
67,68
. HAART, even in individuals with CD4 counts above 350, appears to 
significantly reduce necroinflammatory activity of the liver in HIV/HCV co-infected individuals. 
One study found that HIV/HCV coinfected patients had the same fibrosis progression rate as the 
mono-infected HCV patients if their HIV viral load was suppressed to undetectable. In a study of 
26,641 veterans, HIV/HCV co-infection was only an increased risk factor for cirrhosis when 
compared to HCV monoinfection during the pre-HAART era, but not among HIV/HCV co-
infected patients on HAART
69
. Antiviral therapy has also shown to not only decrease fibrosis in 
HIV/HCV co-infected but also liver-related mortality
68
.  In other studies, results were not as 
promising. One meta-analysis of studies conducted in the HAART era, determined that 
HIV/HCV coinfected patients continue to have higher rates of cirrhosis than HCV mono-infected 
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patients. The HIV/HCV coinfected patients receiving HAART did have less cirrhosis, but did not 
fully decrease to the level of the HCV mono-infected
70
. One large study of over 12,000 patients, 
found that HCV infection still increased mortality among HIV infected patients who were on 
HAART
71
.  These data support the rapid initiation of HAART in patients with HCV co-infection 
in order to reduce fibrosis progression, though these patients are likely to still be at higher risk of 
clinical outcome them their mono-infected counterparts.  As in mono-infected patients, fibrosis 
stage is strongly associated with risk of cirrhosis, decompensated liver disease, HCC, or death
72
. 
Importantly, treatment with ART and higher CD4 counts are associated with significantly lower 
risk of poor clinical outcomes.  
HAART can result in direct hepatotoxicity and worsen HCV liver disease. Most liver related 
toxicity to HAART, however, is reversible with discontinuation of the drug.  Severe steatosis 
with lactic acidosis has occurred with the NRTI’s such as didanosine and stavudine, and these 
medications should be avoided in patient with HCV
73
. 
 
HCV on HIV 
While the effect of HIV on HCV natural history is clearly detrimental, the effect of HCV on HIV 
disease is not as well understood. Although there are two large cohorts reporting an association 
between HCV positivity and increased AIDS related clinical events in HIV/HCV infected 
individuals as compared to HIV monoinfected patients, there are several weakness of the study 
design.  Use of HCV antibody may simply serve as a marker of other baseline risk factors, such 
as substance use and psychiatric disease, which increase the risk of poor adherence to ARVs and 
thus poor HIV control 
74,75
.  Most studies show no association between HIV related outcomes or 
virologic suppression and HCV status 
76-79
.  In one large cohort with almost 6000 patients, no 
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association with HCV positivity and increased AIDS-related events in the adjusted analysis, but 
instead an increased in liver related deaths
79
.  The impact of HCV on immune recovery in HIV 
infected patients taking HAART is also controversial.  The large cohort study mentioned above 
did not identify a difference in immune reconstitution in co-infected as compared to HIV-
monoinfected patients 
79
 . Initial data from the Swiss HIV Cohort Study reported that HCV 
positivity was associated with a lesser CD4 count recovery
75
; however, with extended follow-up 
(4 years) this association was lost
80
. A meta-analysis reported CD4 cell count response in 
HIV/HCV co-infected individuals was on average 33.4 cells/mm
3
 lower at 48 weeks as 
compared to the HIV monoinfected group (54).  This meta-analysis did not report longer term 
results. Thus while short term CD4 reconstitution may be blunted, this does not appear the case 
beyond 48 weeks.  Furthermore, discordance between absolute CD4 counts and CD4 percentages 
has been noted in patients with more advanced liver disease, due to possible splenic 
sequestration
81,82
.  Clinicians should assess CD4 percentage in addition to the absolute count 
when evaluating response to HAART in patients with HCV and sequelae of liver disease. 
Management 
The increased risk of liver disease progression and associated mortality, and the burden of 
healthcare utilization associated with this patient population argue for increased attention to 
evaluate and manage liver disease in all HIV/HCV co-infected patients.  Such management 
considerations include harm reduction counseling, vaccination against other hepatitides, 
assessment of liver disease stage/severity, and evaluation for medical treatment.  
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Harm reduction 
Education remains a key intervention for HIV/HCV infected patients. Emphasis on approaches 
to reduce transmission in patients with ongoing risk factors is especially important. It is reported 
that the prevalence of HCV infection is as high as 77% in HIV-infected IV drug users 
83
. Use of 
needle exchange programs and engagement in substance abuse treatment programs are proven 
interventions to decrease rates of transmission and to maintain sobriety 
84,85
.  As we have become 
increasingly aware of HCV sexual transmission among HIV positive MSM, education on 
condom use and safer sexual practices is highly encouraged.  In particular, clarification of issues 
related to serosorting (HIV positive men choosing to have unsafe sex with other HIV positive 
men) in the HIV-infected MSM community is critical due to the risk behaviors reported in this 
group of patients
86
. 
Alcohol use should also be addressed so as to reduce the progression to liver disease.  Alcohol 
abuse is frequent among HCV carriers, and in one study up to 40% of persons with chronic HCV 
were considered problem drinkers
87
.  Alcohol consumption is known to cause accelerated 
progression of liver fibrosis, higher frequency of cirrhosis, and increased incidence of 
hepatocellular carcinoma.  Patients with alcohol abuse and concomitant HCV are known to have 
worsened survival than for either disease alone
88
. Furthermore, alcohol use causes reduced 
interferon responsiveness and worsen treatment outcomes for patients that will eventually go on 
to obtain HCV medical therapy. Though some studies suggest that only moderate to heavy 
alcohol consumption (greater than 40g per day) affects progression to cirrhosis
89,90
,many other 
studies have shown a dose response association with alcohol intake and worsened liver fibrosis 
even in patients who were minimal drinkers
88,91-93
. HIV/HCV co-infected patients should be 
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encouraged to maintain complete abstinence of alcohol.  Studies have shown that HCV persons 
aware of their diagnosis will reduce their alcohol intake
19
.   
Vaccinations against hepatitis A and B should be performed in all patients that do not show 
immunity to chronic infection.  An isolated Hepatitis B core antibody is more frequent in HIV 
positive and Hepatitis C positive persons and should not be associated with immunity
94
.  One 
study found that these patients have a good immune response to vaccine, with a 74% response 
rate, and therefore HIV positive patients with only HepBcAb should also be immunized.  In 
general, HIV positive patients have reduced immunogenicity to the standard three dose HBV 
vaccine series, with seroconversion between 17.5% to 72%
95
. Some studies suggest that a lower 
CD4 count at the time of vaccination, particularly CD4<200, is associated with reduced 
protective immunity
96,97. Therefore, the recommendation is to delay vaccination until a patient’s 
CD4 count is higher than 200. Other factors such as HIV viral load and CD4 nadir also decrease 
immunogenicity to HBV immunization, regardless of CD4 count at the time of immunization, 
and enhanced vaccine strategies, such as double-dosing, can improve immunogenicity among all 
HIV positive persons. A large randomized controlled trial showed that HIV positive adults 
vaccinated with 4 double dose HBV vaccine series had a significantly greater response to 
vaccine than the persons receiving standard HBV immunization (82% response versus 65%).  
Immunogenicity can also be improved using double-dose of the combined HBV and HAV 
vaccine (Twinrix) using standard 3 dose scheduling series
98
.  Double-dosing of HBV vaccine 
should be considered in all HIV/HCV co-infected individuals in order to increase the chance of 
obtaining protective immunity in this group of at-risk patients.  
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Fibrosis Staging 
Fibrosis is a wound healing response to liver injury. In the HIV/HCV co-infected patient there 
are multiple etiologies of liver injury including chronic hepatitis co-infection, antiretroviral drug 
toxicity, opportunistic infections, non-alcoholic fatty liver disease, and/or alcohol use.  
 
Although current Food and Drug Administration (FDA) approved therapies offer improved 
response rates, the therapy remains complex, difficult to tolerate and not always effective. 
Current treatment guidelines only recommend treating patients that are at greatest risk for disease 
progression.  This recommendation is inextricably tied to the fact that we haven’t had safe, 
tolerable, effective treatments for HCV and so the benefit of treatment has to be weighed with 
the risk of adverse events, and the likelihood that a person will eventually develop liver disease. 
Staging allows physicians to determine if deterring therapy is preferable for patients without 
significant disease. As therapies improve in both tolerability and efficacy, with all oral regimens 
and lower pill burdens, staging may become obsolete as we begin to treat all-comers with HCV 
infection. For now, staging all HIV/HCV co-infected patients is recommended.   
Findings have been consistent in that there is little association between ALT or HCV RNA and 
the degree of histopathologic fibrosis. Almost 25% of HIV/HCV infected patients with normal 
liver enzymes have advanced fibrosis on liver biopsy
99
.  As a result, in patients without obvious 
signs of cirrhosis or liver disease, the gold standard for determining the degree of fibrosis is liver 
biopsy.   Though the biopsy has great specificity, it is still prone to sampling error and 
interobserver variation, as only a small portion of the liver is taken for pathologic evaluation
100
. 
As a result, we can only assert that the degree of liver fibrosis is at least as extensive as seen on 
biopsy.  The biopsy assesses for both grade and stage of liver disease. METAVIR is a validated 
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scoring system that assesses liver damage through histological lesions. The grade(A0-A3) 
reflects the extent of necroinflammatory injury, while the stage(0-4) reflects the extent of fibrosis 
and whether cirrhosis is present.   
Though the biopsy is still the most accurate measure of liver fibrosis, it is invasive, expensive, 
and not without risk to patients such as pain, bleeding, or death
101
.  As a result, non-invasive tests 
such as serum biomarkers and ultrasound elastography are being used as alternatives to biopsy.   
Many scoring indices have been developed and evaluated for possible replacement of the liver 
biopsy, such as the FibroTest, Forn Index, APRI score, Hepascore, Fibrometer, SHASTA, and 
Fib-4. These scoring systems include various combinations of biomarkers such as platelets, liver 
enzymes, alpha2macroglobulin, apolipoproteins, hyaluric acid, and other variables. In one study 
that evaluated and compared all non-invasive biomarker tests, Fibrometer was found to have the 
highest accuracy (71%) when compared to biopsy for classifying patients with higher fibrosis 
scores (greater than or equal to 2). All other biomarker indices had much lower accuracies. As a 
result, biomarkers may help to determine pre-test probability for extent of fibrosis but they are 
generally too inaccurate to facilitate treatment decisions.  
Transient elastography (Fibroscan) is another noninvasive method of detecting liver fibrosis that 
has gained popularity and widespread use in Europe.  This technology uses ultrasound vibrations 
to transmit an elastic shear wave through the liver. The velocity of this wave correlates with 
tissue stiffness, such that the faster the wave travels, the stiffer the liver.  The diagnostic 
accuracy of transient elastography is not as good in HIV/HCV co-infected patients as compared 
to HCV mono-infected patients, but is most reliable at determining when a patient has 
cirrhosis
102
.  For all Fibroscan studies of HIV/HCV co-infected individuals, liver stiffness has 
been significantly associated with extent of fibrosis, but the accuracy for determining exactly 
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which stage of fibrosis the patient lives has been only been reliable in cirrhotics
103-105
. The 
elastography has been shown to be more accurate in predicting fibrosis than other serum 
biomarkers such as the Fib-4 or APRI score
103
. When using a cut-off value of 12.3kPa, TE 
accurately identifies people with cirrhosis 83% of the time
102
. Most of the discordancy in results 
with Fibroscan is from an over estimation of fibrosis as compared to biopsy.  In one study, a 
subsample of the patients with discordant results had biopsies from clinical work-ups prior to 
study participation.  These biopsies were evaluated and almost half had more advanced fibrosis 
on previous biopsy than on study biopsy, leading us to believe that in at least some 
circumstances, biopsy may actually underestimate fibrosis.   When using a cut off value of 
14.6kPa, TE had a positive predictive value of 86%, and a negative predictive value of 94% for 
cirrhosis. Only 5% of patient with an LS measurement of <14.6kPa had cirrhosis, and 17% who 
had an LS measurement >14.6kPa did not have cirrhosis, though most had Stage 2 or greater
104
. 
Defining cut off values for moderate or minimal fibrosis has proved more difficult and TE 
cannot be reliably used to determine these situations.  
Many physicians would withhold or delay treatment if liver histology displays a fibrosis stage 
less than or equal 2, since these individuals are regarded as slowly progressive
106,107
.  Treatment 
should be deterred until more efficacious and tolerable therapies are available.  Treatment is 
advised for those with more advanced fibrosis such as stage 3 or greater. 
Goals of Therapy 
Unlike HIV, it is possible to completely eradicate HCV from the human body and cure people of 
the disease.  The current definition of cure is not a clinical outcome but rather a virologic 
surrogate typically defined as a sustained virologic response, or undetectable HCV viral load, 24 
weeks post treatment.  While most trials used SVR24 as their virologic endpoint, new data show 
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that SVR12 and SVR24 are highly concordant. In evaluating 3 large clinical trials with over 
1500 patients, the concordance rate of SVR12 and SVR24 was over 98%
108
. As a result, SVR12 
is an acceptable primary endpoint in clinical trials and clinical practice, though follow-up HCV 
RNA should be obtained for the minority of individuals who are late relapsers.  
Though the measurement of clinical cure is a surrogate marker, SVR has been shown to be 
associated with reduced clinical outcomes and improved mortality.  In one large retrospective 
study of HIV/HCV co-infected individuals followed for approximately 20 months post-
treatment, patients that reached an SVR had significantly less overall mortality, liver-related 
death, and liver decompensation
109
.  The difference in hepatocellular carcinoma was not 
significant perhaps due to small numbers; there was no person that developed HCC in the group 
that responded to treatment versus 9 persons in the group that did not achieve SVR.  In a large 
prospective study of 22,942 patients all-cause mortality was substantially reduced in patients 
achieving an SVR, such that hazard ratios of 0.7, 0.64, and 0.51 were achieved for genotypes 1,2, 
and 3 respectively
110
.  
 
Treatment 
Interferon and Ribavirin 
The current guidelines for treatment of HCV in an HIV infected patient consists of pegylated 
interferon-alpha once weekly with weight based ribavirin
111
. 
Interferons are naturally occurring proteins that are known to play a role in the control and 
eradication of human viruses
112
.  Interferon-alpha was used as an early therapy for chronic HCV 
even prior to its distinct identification, when patients were thought to have non-A, non-B 
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hepatitis.  Eventually, interferon-alpha was shown to have long standing eradication of the virus 
in a small sub-set of HCV mono-infected individuals and became the standard of treatment.  A 
study of 80 HIV/HCV co-infected patients was published in 1996, and showed a sustained 
virologic response in 18% of patients taking interferon-alpha three times a week for one year
113
.   
Though interferon showed promise in treating a subset of patients infected with HCV, the 
addition of ribavirin to the treatment regimen improved treatment outcomes substantially.  
Ribavirin is a guanosine analogue that has activity against many viruses, though its exact 
mechanism of action against HCV is unknown.   Initial studies with ribavirin monotherapy 
showed minimal decrease in transaminases, and no decrease in viral levels or virologic 
elimination with prolonged therapy
114
. Interestingly, when used in combination with interferon-
alpha, clinical trials showed a decrease in the rate of relapse and greater success of SVR.  
Though interferon and ribavirin revolutionized the therapy for chronic HCV, efficacy still 
remained low and side effect profiles were poor.  In an effort to decrease the number of 
injections (three times a week), and potentially increase efficacy, pegylated interferon was 
created.  With the addition of a polyethylene glycol molecule, interferon- alpha showed a 70-fold 
increase in serum half –life, a 3-fold greater peak activity and other pharmokinetic 
improvements
115
. Clinical trials in co-infected individuals showed increased efficacy with 
pegylated interferon as compared to standard interferons
116-119
. 
The first pivotal trial to compare these crucial therapies in the HIV/HCV co-infected population 
was the APRICOT trial.  This trial is the largest international trial to date to show treatment 
efficacy in people coinfected with HCV and HIV, and is the only trial to include a monotherapy 
arm
116
.  868 co-infected persons were randomized to one of three regimens: peginterferon alfa-2a 
plus ribavirin, peginterferon alfa-2a plus placebo, or interferon alfa-2a plus ribavirin.  
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Participants were treatment-naïve and had compensated liver disease, including 16% of patients 
with bridging fibrosis or cirrhosis, and 85% were on anti-retroviral therapy.  Due to concerns of 
drug-drug interactions with ART, a fixed-dose of ribavirin was used, regardless of participant 
weight.  Overall, a greater number of patients achieved an SVR in the pegylated interferon and 
ribavirin arm than any other group.  For patients with genotype 1, an SVR of 29%, 14%, and 7% 
were achieved for the pegylated interferon plus ribavirin group, pegylated interferon 
monotherapy, and standard interferon plus ribavirin group, respectively.   The SVR for 
genotypes 2/3 were higher: 62%, 36%, and 20% respectively.  Characteristics associated with 
greater response to therapy were non-genotype 1 virus and an initial viral load <800,000, 
variables similar to that of HCV mono-infected patients.  Importantly, CD4 counts and use of 
ART were not associated with treatment response.  Subsequently many other trials showed the 
superiority of pegylated interferon versus standard interferon in achieving an SVR among 
HIV/HCV coinfected patients, with SVR’s for genotype 1/4 ranging from 14-35%, and SVR’s of 
44-73% for Genotypes 2/3. 
It is clear that ribavirin plays a role in aiding and sustaining viral clearance. In a large study of 
1311 patients with chronic hepatitis C mono-infection, higher doses of weight-based ribavirin 
rather than fixed-dose ribavirin led to greater SVR rates
120
.   Two trials of HIV/HCV co-infected 
participants did use the higher, weight dose regimen and achieved SVR rates of 35-38% which 
was somewhat higher than in the APRICOT trial of fixed dose ribavirin. That said, the lack of 
direct comparison of fixed-dose versus weight-based ribavirin in trials of HIV/HCV co-infected 
patients, makes it impossible to state whether this regimen has greater efficacy for HIV/HCV co-
infected patients. Because it is clear that weight based ribavirin has improved efficacy among 
HCV mono-infected patients, guidelines recommend weight based therapy for co-infected 
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patients as well, though there are no randomized controlled trials to support this 
recommendation.  
Despite increased efficacy with pegylated interferon and ribavirin for HIV/HCV co-infected 
individuals, the rates of SVR are still less than that of mono-infected patients.  There are many 
different possibilities for this lower response rate including, greater discontinuation due to side 
effects, higher baseline HCV viral loads, immunological defects that worsen viral clearance, and 
suboptimal doses of ribavirin.  Even in a randomized controlled trial of 104 co-infected patients 
matched by age, sex, and genotype to HCV monoinfected cohort, the SVR rates were still lower 
among co-infected participants( 27.3% vs. 56.4% for genotype 1, and 52% vs. 88% for genotype 
2/3)  despite all patients receiving peginterferon-alpha 2a and weight based ribavirin
121
. 
 
Protease Inhibitors 
Though interferon and ribavirin were the first drug combination to show cure in a subset of HCV 
patients, the regimen is limited by its long treatment duration, difficult side effects, and overall 
poor response rates.  As a result, new drugs are rapidly becoming available to improve these 
adversities and cure more HCV infected persons.  Efforts to improve outcomes are focused on 
producing antivirals with activity directly against the hepatitis C virion, rather than the traditional 
immunomodulating agents on which we have previously depended. 
2011 marked the approval of the first direct acting antiviral therapies against HCV and though 
they continue to be administered with peg-IFN and ribavirin, they have significantly increased 
the chance of cure among chronically infected HCV patients. Telaprevir and Boceprevir are new 
HCV therapies that act directly on HCV NS3/4A protease enzymes to inhibit viral replication.  
The NS3 is a viral protein that, with its cofactor NS4a, produces HCV protease activity
122
. This 
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HCV NS3/4a complex catalyzes cleavage of the single HCV polypeptide into its functional 
components and is essential for viral replication. These (DAA’s) direct acting antivirals have 
significantly increased the rate of SVR achieved in the HCV mono-infected population, 
increasing the number of patients appropriate for treatment and revolutionizing the care of 
chronically infected HCV patients.   
Initial studies showed that despite a high potency for reducing viral load, these medications had a 
low barrier to resistance and thus would still need to be given with an anti-viral “backbone.” 
Telaprevir monotherapy was given for 14 days and resulted in a 5 log reduction in HCV viral 
load. Unfortunately there was significant viral breakthrough, and a majority of these patients had 
resistance mutations
123
. Even in the patients that experienced complete viral suppression at 14 
days, there was emergence of a virus that contained low level resistance mutations. All patients 
with virologic failure in the phase 2 trials for boceprevir emerged with resistance mutations. 
Fortunately, HCV appears to convert back to wild type virus with time and some studies have 
shown that retreatment with a protease inhibitor is possible in previously exposed patients.  That 
said, combination therapy to reduce the emergence of resistance is necessary.   
Telaprevir 
In the pivotal phase III trial ADVANCE, triple therapy of telaprevir, peginterferon, and ribavirin 
obtained SVR rates of 75% as compared to 44% percent in the standard of care arm
124
.  Patients 
taking telaprevir who achieved an eRVR (HCV RNA<25IU/ml at both 4 and 12 weeks) stopped 
therapy at 24 weeks, while those that did not stopped therapy at the typical 48 week mark.  All 
patients were treatment naïve and telaprevir was given TID for 12 weeks in combination with 
peginterferon alpha-2a and weight-based ribavirin, followed by additional peginterferon and 
ribavirin for a total treatment course of 24 or 48 weeks 
124
. The patients receiving telaprevir for 
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12 weeks, achieved SVR rates of 75% as compared to only 44% in persons receiving standard of 
care (peginterferon and ribavirin.)   The ILLUMINATE trial again proved that a shorter duration 
of therapy was as effective for patients who achieved eRVR, 
125
. Among patients who achieved 
an eRVR, the SVR rate in the 24-week treatment arm (92 percent) was noninferior to the SVR 
rate in the 48-week treatment arm (88 percent). Telaprevir was also shown to be effective in 
patients that had previously failed interferon/RBV HCV therapy 
126
.  The overall SVR rates in 
the telaprevir arm were 64% compared to 17% in the patients that received peginterferon and 
ribavirin only. Among the patients that had cirrhosis, the SVR rates were 49% in the telaprevir 
arm versus only 8% in the standard of care arm. The primary side effects of telaprevir were rash 
and worsened anemia.   
Boceprevir showed similar improvements in SVR rates.  In the Phase III SPRINT-2 trial, 
treatment naïve patients with genotype 1 were randomized to receive either standard of care 
versus response guided boceprevir treatment versus boceprevir treatment for the full treatment 
duration of 48 weeks
127
.  All patients received peginterferon and ribavirin for a 4 week lead in 
phase followed by triple drug therapy.  Patients were analyzed separately based on race. For 
nonblack patients, patients who received response guided treatment had SVR rates of 67%, and 
black patients who received response guided therapy had response rates of 42%, and for patients 
receiving full 48 week course 53%.  The SVR rates for patients who achieved an eRVR were 
97% for whites and 87% for blacks.  Boceprevir was also shown to improve cure rates for 
previous non-responders, though null responders were not studied.  Prior non-responders who 
received full 48 week triple therapy had SVR rates of 52%, and prior relapsers had SVR rates of 
75%
128
.  Anemia is the most common and problematic side effect of boceprevir, and over 40% of 
patients on boceprevir needed erythropoietin in most trials.   
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The protease inhibitors have not been approved for patients with HIV/HCV co-infection, though 
initial data show promising results and many people are treating patients off-label.  The results of 
the phase II trial for telaprevir use in HIV/HCV co-infected patients with HCV genotype 1 have 
been announced
129
. This study consisted of two groups: 1) 13 HIV/HCV co-infected patients 
with CD4 counts greater than 500 without need for ART’s and 2) 47 co-infected participants 
with stable HIV suppression on either efavirenz plus truvada or boosted atazanavir plus either 
lamivudine or emtricitabine.  Patients were randomized to receive telaprevir (12 weeks) or 
placebo plus interferon alpha-2a plus fixed-dose ribavirin for a total of 48 weeks.  Telaprevir 
dose was increased to 1125mg TID for patients on efavirenz due to a known drug-drug 
interaction leading to reduced telaprevir levels. Overall, 74% of patients on telaprevir reached an 
SVR compared to an SVR rate of 45% in the standard of care arm.  Participants experienced 
more side effects on telaprevir, specifically rash, pruritus, nausea, and dizziness. Though anemia 
was equally as common in both arms (18%), participants were more likely to receive blood 
transfusions and erythropoietin-stimulating agents in the telaprevir group. Finally, there was no 
HIV virologic breakthrough in either arm, and though absolute CD4 counts dropped as total wbc 
decreased, the CD4 cell percentage remained stable.  
Results of the phase IIb trial for boceprevir showed similarly encouraging results for HIV/HCV 
coinfected patients. This study enrolled 100 previously untreated HIV/HCV coinfected patients 
with genotype 1 virus and randomized them to either boceprevir 800mg TID or placebo plus 
weight-based pegylated interferon alpha-2 and weight-based ribavirin for a total of 48weeks of 
therapy
130
.   As done in mono-infected trials, there was a 4-week lead in phase in which the 
participants received only interferon and ribavirin followed by either placebo or boceprevir for 
12 weeks, completing 48 weeks of treatment with interferon ribavirin.  All patients had 
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undetectable HIV viral loads on ART, and most patients were on boosted protease inhibitors 
with 2NRTI’s, though there were a total of 15 patients on raltegravir.  The SVR rate was 60.7% 
in the boceprevir group as compared to 26.5% in the standard of care arm.  20% of participants 
discontinued therapy due to adverse events in the Boceprevir group as compared to only 9% in 
the placebo arm.  Overall, there were more reported side effects in the boceprevir group, with 
anemia being the most numerous complaint, noted in 41% of patients on boceprevir.  There were 
a few patients that had HIV virologic break through near the end of therapy, though this number 
was not different between groups (3 vs. 4 patients in boceprevir vs. control group).  
Current trials of telaprevir and boceprevir are in Phase III and are evaluating response guided 
therapy.  
Drug-drug interactions with Protease Inhibitors 
It is important to note that HCV protease inhibitors are metabolized by the cytochrome P450 
system, and therefore have potential for significant drug-drug interactions, particularly for 
HIV/HCV co-infected patients on NNRTI’s or HIV protease inhibitor therapies.  There are 
several noted drug-drug interactions between ART and the HCV protease inhibitors.  
Important drug-drug interactions were found in an open-label drug interaction study of 
boceprevir and several protease inhibitors
131
. Coadministration of boceprevir and boosted 
lopinavir and darunavir significantly lowered the AUC of boceprevir, raising concern over 
potential HCV treatment failure when these drugs are given in combination. Data that attempt to 
determine the association between various boceprevir levels and SVR rates are unclear, making 
this drug-drug interaction difficult to interpret.  Particularly worrisome is the fact that boceprevir 
lowered the trough concentrations of atazanavir, lopinavir, and darunavir by 49, 43%, and 59% 
respectively.  These data raise concerns about provoking HIV virologic breakthrough in patients 
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on these regimens. Though there was no evidence of increased HIV virologic breakthrough in 
phase 2 trials of boceprevir when these combinations were used, it is currently not recommended 
to combine these drugs.  A similar study evaluating co-administration of raltegravir and 
boceprevir did not show any significant effects on exposure of either of the drugs
132
.  A 
raltegravir based HIV regimen is currently the best choice when treating HIV/HCV coinfected 
patients with boceprevir.   
 
Investigational Drugs 
The expectation for new drug development will be to create combination therapies that have 
better cure rates, less side effects, require decreased duration of treatments, and can be used 
without interferon. 
Newer Protease Inhibitors 
Current protease inhibitors are given three times daily, have significant side effect profiles such 
as pruritic rash and anemia, and easily develop resistance.  The new protease inhibitors have 
been developed in order to reduce the dosing schedule from thrice daily to once daily, with the 
hopes of better side effect profiles and greater efficacy. Two of the newest protease inhibitors 
that are currently in phase III development are Simeprevir (TMC435) and Faldaprevir (BI 
2010335). In HCV mono-infected patients taking once daily simeprevir plus 
peginterferon/ribavirin, SVR rates were achieved in 86% of patients
133
.  Of note, patients 
received response guided therapy such that patients with undetectable HCV viral loads at week 4 
received 24 weeks of therapy, while all others received 48. Unlike current protease inhibitors, 
SVR rates were similar for both genotype 1a and 1b.  Simeprevir will likely be used in 
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HIV/HCV co-infected individuals and has been evaluated with ARTs.  Simperevir is not 
recommended with efavirenz due to reduce levels of simeprevir, but appears to be safe with 
raltegravir, rilpivirine, and tenofovir
134
.  
Faldeprevir, once daily, plus peginterferon/ribavirin for 24 weeks led to SVR rates of 83% in 
HCV mono-infected patients, and side effects were similar to those of interferon and ribavirin 
therapy
135
.  This protease inhibitor is currently in phase III development and being studied with 
BI’s polymerase inhibitor BI 207127 and ribavirin to create an interferon-free, all oral regimen. 
Results of the phase II trial showed a 43–50% SVR12 in genotype 1a and 57–80% in genotype 
1b for patients with compensated liver cirrhosis, who took 12 weeks of triple oral therapy
136
.  
The NS5A inhibitors 
NS5a is a metalloprotein that is part of the HCV replication complex, a membranous web of 
nonstructural proteins essential for viral replication.  Though the exact mechanism of NS5A 
replication regulation is unclear, inhibitors of the protein in replicon assays has been potent
122
.  
These drugs are active against all genotypes and have potent viral suppression but have a low 
barrier to resistance. They are mostly being used in combination therapy with other oral therapies 
so as to create interferon-free regimens.  Daclatasavir (BMS-790052), a new NS5A inhibitor is 
currently being evaluated in Phase III trials for both mono-infected and HIV/HCV co-infected 
individuals.  
Drug-drug interactions between common ARTs and daclatasvir have been studied. Daclatasvir 
appears to have no effect on the drug levels of tenofovir, efavirenz, or boosted atazanavir
137
. 
These ARTs do exhibit some change in exposure to the NS5A inhibitor, but adjusting daclatasvir 
dosing up when combined with efavirenz, and decreasing the dose when given with boosted 
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atazanavir can overcome this, and all trials are using dose-adjusted combinations of daclatasvir 
for co-infected individuals.  
NS5B Polymerase Inhibitors 
These drugs can be divided into two classes, the nucleotide inhibitors and the non-nucleoside 
inhibitors. The non-nucleotide inhibitors bind to one of three allosteric binding sites outside of 
the enzymatic region, creating conformational change at the active site which induces 
polymerase inhibition.  These drugs are genotype 1 specific, have a low barrier to resistance, and 
are not as far along in development as other classes. That said, they may be helpful in building 
drug combinations that act on different parts of the HCV virus, creating more potent oral 
combination regimens.   
The nucleotide polymerase inhibitors bind directly to the HS5B active polymerase site. They 
have shown extreme potency and high barrier to resistance, and are currently being considered 
the therapeutic backbone of interferon free regimens.  Sofosbuvir (GS-7977) is the furthest along 
in production. It has activity against all genotypes, is extremely potent, with a good side effect 
profile, and once daily oral dosing.  
Results from the ELECTRON study showed extremely promising interim results for interferon-
free therapy. After 12 weeks of GS-7977 in combination with ribavirin for patients with HCV 
genotype 2/3, 100% of participants reached an SVR
138
.  Of the 25 treatment naive HCV 
genotype 1 patients treated with Sofosbuvir (GS-7977) and ribavirin for 12 weeks, 84% achieved 
an SVR24.  Side effects were minimal in all studies and there were no discontinuations due to 
adverse events.   
Sofosbuvir showed similarly potent viral kinetics in HIV/HCV co-infected individuals in a phase 
1b trial, with a >1.5log10 HCV viral reduction in 24 hours
139
.  Sofosbuvir combined with 
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ribavirin is already being studied in HIV/HCV co-infected patients with HCV genotypes 2/3, and 
a shortened duration of therapy (12 weeks) is being evaluated.  There have been no clinically 
significant interactions between sofosbuvir and efavirenz, rilpivirine, boosted darunavir, 
raltegravir, tenofovir, and emtricitabine in healthy volunteers
140
. Drug interactions may be 
different in persons infected with HIV and hepatitis C as compared to healthy controls and 
therefore careful monitoring must take place in Phase III clinical trials. 
One of the most exciting studies of 2012, was the combination of Sofosbuvir (GS-7977) and 
daclatasvir (BMS-790052) with and without ribavirin
141
.   88 patients with genotypes 1, 2, and 3 
received 24 weeks of therapy. The SVR4 rate was 100% in genotype 1 and over 85% in 
genotype 2/3, regardless of ribavirin use.  Ribavirin was associated with anemia, but all other 
side effects were mild including fatigue, nausea, and headache. Importantly, there was no 
association between SVR and IL28 genotype, ribavirin use, or viral subtype, of which most were 
the difficult to treat 1a.  A current trial is evaluating the same treatment but for only 12 weeks 
treatment duration.   Gilead will not pursue additional phase III trials with BMS using daclatasvir 
in this drug combination, but instead has its own NS5A inhibitor in which they are conducting 
trials. Certainly, when daclatasvir (BMS-790052) and Sofosbuvir (GS-7977) become FDA 
approved, clinicians will be able to use them as they feel will most benefit their patients.  
Gilead’s NS5A inhibitor (GS-5885) 
Data from the ELECTRON 4 trial are promising in Genotype 1 patients. Treatment naïve 
patients and prior null responders were randomized into 4 arms where patients were given 
Sofosbuvir plus ribavirin with/without Gilead’s NS5a inhibitor.  100% of participants in the 
triple therapy arm were cured, including 4 of 9 null responders who were available for evaluation 
at the end of the study.  This compared with 84% in the dual therapy arm for treatment naïve 
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patients, and only 10% in the prior null responders.  Anemia was associated with ribavirin use, 
but all other side effects were minor.  Gilead has announced the phase III ION-I study evaluating 
a fixed-dose combination of sofosbuvir and their NS5A inhibitor alone or with ribavirin for 12 
and 24 weeks.  These results will be eagerly awaited to see if they are as effective as the 
daclatasvir/sofosbuvir data. Certainly these fixed dose combinations, if shown to have good 
efficacy, will be tried in the HIV/HCV co-infected populations.  
 
Liver Transplant in the HIV/HCV Co-infected Patient 
Despite advancement’s in HCV therapies, many HCV/HIV co-infected individuals will develop 
end-stage liver disease, leaving liver transplant as their only choice of therapy. Furthermore, 
some patients with compensated cirrhosis will develop acute de-compensation while being 
treated for HCV with interferon containing regimens. In one of the largest trials of HCV/HIV co-
infected patients (APRICOT trial), 7.5% of the cirrhotic patients treated with interferon 
developed persistent decompensated cirrhosis or died due to hepatic de-compensation while on 
treatment
142
.  Many of these patients were on didanosine, an antiretroviral now known to be 
associated with hepatic dysfunction in HCV/HIV coinfected individuals and therefore currently 
contraindicated in such patients. That said, due to the increased risk of de-compensation, it is 
imperative to have liver transplant available to HIV/HCV co-infected cirrhotic patients if they 
are to be treated with interferon.  
Prior to HAART, HIV was considered an absolute contraindication to transplant due to 
immunosuppression and poor long-term survival of HIV infected individuals
143
. With the 
introduction of more effective antiretroviral therapies, early transplant outcomes for HIV 
infected individuals were shown to be similar to their uninfected counterparts
144-146
.  
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Unfortunately, HCV infection was a risk factor for worsened survival after liver transplantation.  
Two recent prospective cohort studies conducted in the United States and Spain showed 
worsened patient and graft survival for HIV/HCV co-infected patients as compared to HCV 
monoinfected controls
147,148
.  The multicenter US study found a 3-year patient and graft survival 
rate of 60% and 53% respectively for HCV/HIV coinfected individuals, compared to 79% and 
74% for the HCV monoinfected.   Five year survival rate in the Spanish study was 71% in the 
monoinfected and 54% in the HIV/HCV coinfected.  Importantly, multiple studies have found 
specific risk factors particularly associated with poor outcomes among the HIV infected 
cohort
147-149
. Patient predictors of poor outcome consist of HCV genotype 1, higher pre-
transplant MELD score, BMI <21, and combined kidney-liver transplantation. Other variables 
associated with worse outcomes are older donor age, anti-HCV-positive donor, and centers that 
perform less than 1 liver transplant per year in HIV positive patients. When evaluating the subset 
of patients that do not meet these poor risk criteria, all studies show that this more favorable 
subset of HIV/HCV coinfected individuals have the same survival and outcomes as the HCV 
monoinfected.  These data suggest that liver transplantation can indeed prolong survival for HCV 
patients coinfected with HIV, but appropriate risk stratification should be performed before this 
option is considered.  That said, developing effective HCV therapy that would obviate the need 
for transplantation would be most beneficial for the long-term survival of the HCV/HIV co-
infected population.  
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